Linked guidances/guidelines are in English, unless stated otherwise. Language codes are given according to ISO 639-1 (i.e., English en, French fr, German de, Spanish es, Danish da, Portuguese pt, Japanese ja, Chinese zh, Arabic ar,…)
Although links to documents are considered current with 21 May 2013, you should always consult websites of the respective regulatory body for any updated versions. Documents superseded by newer versions are striken through. While obsolete, previous versions are helpful in dealing with deficiency letters issued for “old” studies. Documents published within the last two years are marked.
UpdatesUD and additionsnew within the last six months: →1, →2, →3, →4.
If you encounter broken links or are acquainted with any missing / updated documents please notify the webmaster.
International Conference on Harmonisation
- Development Safety Update Report; E2F: step 4, Aug 2010 (PDF334KB)
- Structure and Content of Clinical Study Reports; E3: Nov 1995 (PDF471KB)
Q&A: Jun 2012 (PDF158KB)
- Good Clinical Practice; E6(R1): step 4, Jun 1996 (PDF380KB; including IB template)
- General Considerations for Clinical Trials; E8: Jul 1997 (PDF182KB)
- Clinical Safety Data Management: Definitions and Standards for Expedited Reporting; E2A: step 4, Oct 1994 (PDF145KB)
- Statistical Principles for Clinical Trials; E9: Feb 1998 (PDF284KB)
- Validation of Analytical Procedures – Text and Methodology; Q2(R1): step 4, Nov 2005 (PDF180KB)
- Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products – Chemical Substances; Q6A: Oct 1999 (PDF211KB, Decision Trees PDF46KB)
- Pharmaceutical Development; Q8(R2): step 4, Aug 2009 (PDF764KB)
World Health Organization
- Guidelines for GCP for trials on pharmaceutical products (WHO Technical Report Series No. 850, Annex 3): 1995 (PDF104KB)
- Handbook for GCP: 2005 (PDF560KB)
- Prequalification Programme
Information for Applicants: Guidelines: Generics
- Main text: Guideline on Generics – Pharmaceutical Quality and BE (333KB PDF); selected annex and supplement below.
- Annex 7, Presentation of BE Trial Information (BTIF): Jan 2010 (DOC440KB, ZIP/DOC245KB),
Aug 2005 (DOC424KB, ZIP/DOC244KB)
- Supplement 1 (Dissolution testing): Jul 2005 (PDF103KB)
- Guideline on the requalification of prequalified dossiers: 2010 (PDF66KB)
Multisource (Generic) Products: Draft Revision, 2005 (PDF277KB), 1998 (PDF666KB)
- International Comparator Products
- Reproductive Health medicines: Mar 2012 (PDF121KB)
- Medicines for HIV/AIDS and related diseases: Feb 2012 (PDF56KB)
- Anti-malarial medicines: Feb 2012 (PDF67KB)
- Anti-tuberculosis medicines: Feb 2012 (PDF29KB)
- Influenza-specific antiviral medicines: Jun 2009 (PDF45KB)
- International Comparator: Draft Revision, 2005 (PDF142KB)
- Biowaivers
- General notes on Biopharmaceutics Classification System (BCS)-based biowaiver applications: Nov 2011 (PDF49KB),
Draft 2005 (PDF197KB)
- Application Form: Dec 2008(DOC62KB)
- Additional Strength: May 2012(DOC88KB)
Guidance for Organizations performing in vivo Bioequivalence Studies: Draft 2005 (PDF103KB)
- WHO Expert Committee on Specifications for Pharmaceutical Preparations, Thirty-ninth Report (WHO TRS No. 929, Annex 5); Fixed dose combinations: Jun 2005 (PDF974KB)
- WHO Expert Committee on Specifications for Pharmaceutical Preparations, Forty-sixth Report (WHO TRS No. 970), Annex 4, Guidelines on submission of documentation for a multisource (generic) finished pharmaceutical product for the WHO Prequalification of Medicines Programme: quality part: 2012 (PDF1.0MB)
- WHO Expert Committee on Specifications for Pharmaceutical Preparations, Fortieth Report (WHO TRS No. 937): May 2006 (PDF1.9MB); Annexes 7–9 are available in separate documents:
- Annex 7: Multisource (generic) pharmaceutical products: guidelines
on registration requirements to establish interchangeability (PDF425KB)
- Annex 8: Proposal to waive in vivo bioequivalence requirements for WHO Model List of Essential Medicines immediate-release, solid oral dosage forms (PDF464KB)
- Annex 9: Additional guidance for organizations performing in vivo bioequivalence studies (PDF371KB)
- WHO Expert Committee on Biological Standardization; Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs): Oct 2009 (PDF256KB)
- Handbook Good Laboratory Practice (GLP): 2001 (PDF1.1MB)
-
- Training manual for the trainer: 2001 (PDF2.4MB)
- Training manual for the trainee: 2001 (PDF2.3MB)
European Union (EMA)
EudraLex – The Rules Governing Medicinal Products in the European Union
- Procedure for European Union Guidelines and Related Documents within the Pharmaceutical Legislative Framework: Jan 2009 (PDF102KB)
- Guidelines: Clinical Efficacy and Safety HTML, Multidisciplinary HTML
- Legislation
- Directive 2001/20/EC (Implementation of GCP in the Conduct of Clinical Trials on Medicinal Products for Human Use): Apr 2001 (PDF152KB)
- Directive 2003/94/EC (Principles and Guidelines of GMP in Respect of Medicinal Products for Human Use and Investigational Medicinal Products for Human Use): Oct 2003 (PDF115KB)
- Directive 2004/9/EC (Inspection and Verification of GLP): Feb 2004 (in many European languages and formats [HTML, PDF, TIFF], e.g., PDF247KB en)
- Directive 2004/10/EC (Harmonisation of Laws, Regulations and Administrative Provisions relating to the Application of the Principles of GLP and the Verification of their Applications for Tests on Chemical Substances): Feb 2004 (in many European languages and formats [HTML, PDF, TIFF], e.g., PDF239KB en)
- Directive 2005/28/EC (Principles and detailed Guidelines for GCP as regards IMPs for Human Use, as well as the Requirements for Authorisation of the Manufacturing or Importation of such Products): Apr 2005 (PDF66KB)
- Requirements to the Chemical and Pharmaceutical Quality Documentation concerning IMPs in Clinical Trials: Mar 2006 (PDF141KB)
- Definition of IMPs and NIMPs: Jul 2006 (PDF51KB)
- Additional Information on IMPs: Apr 2007 (PDF41KB)
- GMP, Medicinal Products for Human and Veterinary Use, Annex 13, IMPs: Jan 2010 (PDF66B)
- Bioavailability / Bioequivalence
- Note for Guidance and associated documents
- Bioequivalence: Jan 2010 (PDF236KB), Overview of comments Jan 2010 (PDF1.5MB)
Draft Jul 2008 (PDF436KB) Recommendation on the Need for Revision of NfG on BA/BE: May 2007 (PDF38KB)
- Appendix IV of the Guideline on the Investigation on
BE (CPMP/EWP/QWP/1401/98 Rev.1): Presentation of Biopharmaceutical and Bioanalytical Data in Module 2.7.1: Final Nov 2011 (PDF137KB), Overview of comments (PDF232KB),
Draft Feb 2011 (PDF155KB), Concept paper Apr 2010 (PDF99KB)
Questions & Answers on the BA and BE Guideline: Jul 2006 (PDF118KB
PDF)
Bioavailability / Bioequivalence: Jul 2001 (PDF99KB).
BA/BE for HVDs/HVDPs: Apr 2006; removed in Oct 2007 from EMEA’s site (Deleted – This topic will be addressed in the revision of “Note for guidance on the investigation of bioavailability and bioequivalence” CHMP/EWP/200943/07)
PDF36KB.
Concept Paper: May 2007 (PDF43KB)
- Reflection paper: Advice to Applicants/Sponsors/CROs of BE Studies: Sep 2008 (PDF104KB)
- Modified Release Oral / Transdermals: Jul 1999 (PDF122KB); see also the Q&A-document below.
- Guideline on the pharmacokinetic and clinical evaluation of modified release dosage formsnew: Draft Feb 2013 (PDF395KB)consultation: 2013-09-15
Concept paper May 2010 (PDF78KB)
- Guidelines on oral modified release products and transdermal patches (Section I: quality)new: Drafts Sep 2012 (oral MR products PDF187KB, transdermal patches PDF241KB)
Concept paper Jul 2010 (PDF95KB)
- Pharmacokinetics
- Pharmacokinetic Studies in Man: Oct 1988 (PDF39KB)
- Concept paper on the need for revision of the NfG on the evaluation of the PK of medicinal products in patients with impaired renal function: Jun 2012 (PDF66KB)
- PK Studies in Patients with Renal Impairment: Jun 2004 (PDF213KB)
- Evaluation of the PK of Medicinal Products in Patients with Impaired Hepatic Function: Feb 2005 (PDF92KB)
- PK in the Development of Medicinal Products in the Paediatric Population: Jun 2006 (PDF115KB)
- Reflection paper: Use of Pharmacogenetics in the PK Evaluation of Medicinal Products: May 2007 (PDF61KB)
- Concept Paper on the Development of a Guideline on the Use of Pharmacogenomic Methodologies in the PK Evaluation of Medicinal Products: Apr 2009 (PDF53KB)
- Reporting Results of Population PK Analyses: Jun 2007 (PDF68KB)
- Strategies to Identify and Mitigate Risks for First-In Human Clinical Trials with IMPs: Jul 2007 (PDF83KB)
- Statistical Issues
- Biostatistical Methodology in Clinical Trials*: Oct 1993 (
PDF153KB
PDF).
- Concept paper on the need for a guideline on multiplicity issues in clinical trials: May 2012 (PDF66KB)
- Points to Consider on Multiplicity Issues in Clinical Trials: Sep 2002 (PDF208KB)
- Guideline on missing data in confirmatory clinical trials: Jul 2010 (PDF142KB)
Draft Apr 2009 (PDF99KB) Recommendation for the Revision of the Points to Consider on Missing Data (CPMP/EWP/1776/99): Dec 2007 (PDF35KB) Points to Consider on Missing Data Nov 2001 (PDF38KB)
- Biotechnological and Biological Products, Biosimilars
- Development Pharmaceutics for Biotechnological and Biological Products – Annex to Note for Guidance on Development Pharmaceutics: Oct 1999 (PDF36KB)
- Clinical Investigation of the PK of Therapeutic Proteins: Jan 2007 (PDF98KB)
Draft Jul 2005 (PDF101KB)
- Similar Biological Medicinal Productsnew: Draft Apr 2013 (PDF117KB)consultation: 2013-10-31
Concept paper Nov 2011 (PDF137KB), Final Oct 2005 (PDF106KB) Q&A on biosimilar medicines: Oct 2008 (PDF30KB)
- Requirements for quality documentation concerning biological investigational medicinal products in clinical trials: Mar 2012 (PDF178KB)
- EMA Procedural advice for users of the centralised procedure for similar biological medicinal products applications: Nov 2011 (PDF257KB)
- Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1): Draft May 2012 (PDF128KB)
- Biosimilars containing Biotechnology-Derived Proteins as Active Substance: Quality Issues: Feb 2006 (PDF137KB)
- Concept paper on the revision of the guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues: Sep 2011 (PDF142KB), Biosimilars containing Biotechnology-Derived Proteins as Active Substance: Non-Clinical and Clinical Issues: Feb 2006 (PDF102KB)
- Comparability of Biotechnology-Derived Medicinal Products after a change in the Manufacturing Process – Non-Clinical and Clinical Issues: Jul 2007 (PDF118KB)
Draft Jan 2007 (PDF171KB) Concept paper Feb 2006 (PDF38KB) Final Dec 2003 (PDF194KB)
- Product specific biosimilar guidelines
- Recombinant Human Insulin and Insulin Analogues: Draft Dec 2012 (PDF129KB)
Concept paper Jul 2011 (PDF248KB), Feb 2006 (PDF102KB)
- Somatropin: Feb 2006 (PDF78KB)
- Recombinant Granulocyte-Colony Stimulating Factor: Feb 2006 (PDF89KB)
- Recombinant Erythropoietins: Apr 2010 (PDF133KB)
Draft Jul 2009 (PDF108KB) Concept paper Jul 2008 (PDF43KB) Final Mar 2006 (PDF45KB)
- Low-molecular-weight-heparinsnew: Draft Jan 2013 (PDF167KB)
Concept paper Jul 2011 (PDF252KB), Mar 2009 (PDF63KB) Draft Apr 2008 (PDF55KB) Concept paper Jan 2007 (PDF72KB)
- Interferon alpha: Reflection paper Jun 2009 (PDF97KB)
Draft Oct 2007 (PDF102KB) Concept paper Apr 2006 (PDF72KB)
- Interferon beta: Draft Jan 2012 (PDF155KB)
Concept paper Mar 2010 (PDF179KB)
- Immunogenicity assessment of monoclonal antibodies: Concept paper Mar 2009 (PDF39KB)
- Monoclonal antibodies: May 2012 (PDF211KB)
Draft Nov 2010 (PDF192KB)
- Follicle stimulation hormone: Draft Nov 2011 (PDF159KB)
Concept paper Mar 2010 (PDF125KB)
- Miscellaneous
- Q&A: Positions on specific questions addressed to the Pharmacokinetics Working Party (PKWP)UD: Feb 2013 (PDF403KB) Dec 2012 (
PDF300KB) Sep 2012 (
PDF419KB) Feb 2012 (
PDF282KB) Jan 2011 (
PDF195KB) Jul 2010 (
PDF182KB) Jul 2009 (PDF89KB
PDF) Jun 2009 (PDF94KB
PDF) Jan 2009 (
PDF87KB)
- Scientific Advice & Protocol Assistance: Revision 6, May 2010 (PDF280KB)
- Validation of Bioanalytical Methods: Jul 2011 (PDF159KB), Overview of comments Jul 2011 (PDF2.64MB),
Draft Nov 2009 (PDF135KB) Concept Paper Dec 2008 (PDF52KB)
- Validation of Analytical Procedures. Text and Terminology: Nov 1994; Methodology: Dec 1996 (PDF186KB)
- Test on Samples of Biological Origin: Jul 1989 (PDF39KB)
- Clinical Investigation of Chiral Active Substances: Apr 1994 (PDF52KB)
- Topicals: Nov 1995 (PDF43KB)
- Fixed Combination Medicinal Products: Feb 2009 (PDF92KB)
- Drug Interactions: Jun 2012 (PDF852KB)
Draft Apr 2010 (PDF352KB) Concept Paper Jul 2008 (PDF31KB) Final Dec 1997 (PDF79KB)
- Development Pharmaceutics: Jan 1998 (PDF58KB)
- Dry Powder Inhalers*: Jun 1998 (
PDF45KB
PDF).
- Points to Consider on the Requirements for Clinical Documentation for Orally Inhaled Products (OIP): Apr 2004 (PDF159KB)
- Recommendation on the Need for Revision of Points to Consider on the Requirements for Clinical Documentation for Orally Inhaled Products (OIP): Feb 2007 (PDF36KB)
- Requirements for Clinical Documentation for Orally Inhaled Products (OIP) including the Requirements for Demonstration of Therapeutic Equivalence between two Inhaled Products for Use in the Treatment of Asthma and Chronic Obstructive Pulmonary Disease (COPD): Jan 2009 (PDF271KB),
Draft Oct 2007 (PDF176KB), Appendix 1: Mar 2008 (PDF44KB)
- Guideline on Pharmaceutical Development of Medicines for Paediatric Use: Draft May 2011 (PDF247KB)
- Gender Considerations in the Conduct of Clinical Trials: Jan 2005 (PDF75KB)
- Strategy paper: Acceptance of clinical trials conducted in third countries, for evaluation in Marketing Authorisation Applications: Dec 2008 (PDF31KB)
- Reflection paper on ethical and GCP aspects of clinical trials of medicinal products for human use conducted outside of the EU/EEA and submitted in marketing authorisation applications to the EU Regulatory Authorities: Apr 2012 (PDF293KB)
- Inspections – Good Clinical Practice: Set of 12 documents, Sep 2007 – Jul 2008 (e.g., Investigator Site PDF39KB, Sponsor and/or Contract Research Organisations PDF36KB, Phase I Units PDF31KB, Bioanalytical part, Pharmacokinetic and Statistical analyses of BE Trials PDF99KB, …)
- Inspections – Q&A: Good clinical practice (GCP): 2012 (HTML119KB)
- Reflection paper for laboratories that perform the analysis or evaluation of clinical trial samples: Feb 2012 (PDF167KB)
- Heads of Medicines Agencies / Human Medicines
All pages refer to current documents (PDF).
Danish Medicines Agency (DKMA)
- Bioequivalence and labelling of medicinal products with regard to generic substitution: Feb 2012 (HTML12KB en, HTML12KB da)
USA (FDA)
- Legislation (excerpts from Code of Federal Regulations, CFR)
- Title 21, Vol. 1, Ch. I, Part 11 [21CFR11]): Electronic records; electronic signatures (Overview containing links to Subparts/Sections)
- Title 21, Vol. 1, Ch. I, Part 50 (21CFR50): Protection of human subjects (Overview+links)
- Title 21, Vol. 1, Ch. I, Part 56 (21CFR56): Institutional review boards (Overview+links)
- Title 21, Vol. 1, Ch. I, Part 58 (21CFR58): GLP for Nonclinical Laboratory Studies (Overview+links)
- Title 21, Vol. 5, Ch. I, Part 312 (21CFR312): Investigational NDA (Overview+links)
- Title 21, Vol. 5, Ch. I, Part 320 (21CFR320): BA and BE Requirements (Overview+links)
- CDER’s Manual of Policies and Procedures
- Inspections of Clinical Facilities and Analytical Laboratories Conducting BE Studies Submitted in ANDAs: Dec 2000 (PDF19KB)
- Review of BE Study Protocols: Jul 2006 (PDF26KB)
- Review of BE Studies with Clinical Endpoints in ANDAs: Dec 2006 (PDF25KB)
- Bioavailability / Bioequivalence
- The ‘Orange Book’: 32th Edition, 2012 (PDF10.1MB as of Dec 31, 2011, Cumulative supplement [published monthly], Electronic ‘Orange Book’: Current version [including online search])
Statistical Procedures for BE Studies using a Standard Two-Treatment Crossover Design: Jul 1992 (PDF1.4MB)
Oral extrended (controlled) release dosage forms in vivo BE and in vitro dissolution testing: Aug 1996 (?) (PDF34KB)
- Statistical Approaches Establishing BE: Jan 2001 (PDF130KB)
- BA/BE—General Considerations: Revision 1, Mar 2003 (PDF268KB)
- Food-Effect BA / Fed BE: Dec 2002 (PDF166KB)
- ER / in vitro/in vivo Correlations: Sep 1997 (PDF170KB)
- Biowaivers / BCS: Aug 2000 (PDF54KB)
- BA/BE for Nasal Aerosols / Sprays for Local Action: Draft Apr 2003 (PDF519KB; Statistical Information PDF185KB)
- SUPAC [IR]: Nov 1995 (PDF60KB, 1997 Questions and Answers HTML16KB)
- SUPAC [MR]: Sep 1997 (PDF215KB)
- SUPAC [SS]: May 1997 (PDF118KB)
- BE Recommendations for Specific Products: Jun 2010 (PDF80KB); Individual Product BE Recommendations by API)
- Critical Path Opportunities for Generic Drugs: May 2007 (HTML12KB)
- Handling/Retention of BA/BE Samples: May 2004 (PDF166KB)
- ANDA Checklist for Completeness and Acceptability: Mar 2011 (PDF140KB)
- Model BE Data Summary Tables: Jan 2007 (PDF219KB, DOC634KB)
- Submission of Summary BE Data for ANDAs: Final May 2011 (PDF137KB)
- Self-Identification of Generic Drug Facilities, Sites, and Organizations: Draft Aug 2012 (PDF209KB), Q&A (PDF482KB)
- Biosimilars
- Scientific Considerations in Demonstrating Biosimilarity to a Reference Product: Draft Feb 2012 (PDF576KB)
- Quality Considerations in Demonstrating Biosimilarity to a Reference Protein Product: Draft Feb 2012 (PDF432KB)
- Biosimilars: Q&A Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009: Draft Feb 2012 (PDF177KB)
- Miscellaneous
- Size of Beads in Drug Products Labeled for Sprinkle: May 2012 (PDF148KB)
- Bioanalytical Method Validation: May 2001 (PDF63KB)
- Reviewer Guidance—Validation of Chromatographic Methods: Nov 1994 (PDF703KB)
- Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products: May 1998 (PDF129KB)
- Pharmacokinetics in Patients with Impaired Renal Function—Study Design, Data Analysis, and Impact on Dosing and Labeling: Draft Mar 2010 (PDF318KB), May 1998 (PDF128KB)
- General Considerations for Pediatric Pharmacokinetic Studies for Drugs and Biological Products: Draft Nov 1998 (PDF37KB)
- Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling: May 2003 (PDF222KB)
- Guidance for Industry Providing Regulatory Submissions in Electronic Format—Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications: Revision 2, Jun 2008 (PDF133KB)
- Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers: Jul 2005 (PDF702KB)
- Current GMP for Phase 1 Investigational Drugs: Jul 2008 (PDF132KB)
- Population PK: Feb 1999 (PDF135KB)
- Safety Testing of Drug Metabolites: Feb 2008 (PDF86KB)
- Drug Metabolism/Interactions: Nov 1999 (PDF44KB)
- Drug Interaction Studies—Study Design, Data Analysis, and Implications for Dosing and Labeling: Draft Feb 2012 (PDF827KB)
- Exposure-Response Relationships—Study Design, Data Analysis, and Regulatory Applications: Apr 2003 (PDF221KB)
- Guidance for Sponsors, Clinical Investigators, and IRBs. Data Retention When Subjects Withdraw from FDA-Regulated Clinical Trials: Oct 2008 (PDF75KB)
- Investigator Responsibilities—Protecting the Rights, Safety, and Welfare of Study Subjects: Oct 2009 (PDF163KB)
- Guidance for Institutional Review Boards, Clinical Investigators, and Sponsors: 1998—2012 (HTML8KB)
- Information Sheet Guidance for Sponsors, Clinical Investigators, and IRBs; Frequently Asked Questions–Statement of Investigator (Form FDA 1572): May 2010 (PDF105KB)
- Safety Reporting Requirements for INDs and BA/BE Studies: Draft Sep 2010 (PDF688KB)
- Compilation of International Human Subjects Protections: 2011 (PDF938KB)
- General Principles of Software Validation; Final Guidance for Industry and FDA Staff: Jan 2002 (PDF161KB, HTML39KB)
- Part 11, Electronic Records; Electronic Signatures — Scope and Application: Aug 2003 (PDF215KB)
- Computerized Systems Used in Clinical Investigations: May 2007 (PDF53KB)
- GLP (Non-Clinical Laboratories)
- Compliance Program Guidance Manual: Feb 2001 (PDF117KB, HTML7KB)
Final Rule: Dec 1978 (PDF6.4MB)
Proposed Rule: Oct 1984 (PDF1.7MB, HTML20KB)
- Final Rule: Sep 1987 (PDF3.0MB, HTML34KB)
- Questions and Answers: Jun 1981, Dec 1999, Jul 2007 (PDF52KB, HTML22KB)
- Sponsors, Contract Research Organizations and Monitors: Feb 2001 (PDF80KB, HTML3KB)
- Clinical Investigators: Dec 2008 (PDF240KB, HTML3KB)
Computerized Systems Used In Clinical Trials: Apr 1999 (PDF46KB, HTML12KB); for the current version (May 2007) see CDER’s document linked in the previous section.
- Guideline for the Monitoring of Clinical Investigations: Jan 1988 (HTML9KB)
- Institutional Review Boards: Oct 1994 (PDF293KB)
Canada (HPFB/TPD)
- Conduct and Analysis of Comparative BA Studies: May 2012 (PDF186KB, HTML224KB),
Draft Jan 2010 (PDF190KB, HTML198KB)
- Comparative BA Standards: Formulations used for Systemic Effects: May 2012 (PDF52KB, HTML53KB),
Draft Jan 2010 (PDF58KB, HTML42KB)
- BCS Based Biowaiver: Draft Aug 2012 (PDF121KB, HTML50KB)
- Information and Submission Requirements for Subsequent Entry Biologics (SEBs): Draft Mar 2010 (PDF96KB, HTML71KB)
- Inclusion of Women in Clinical Trials: Apr 1997 (PDF24KB, HTML29KB)
- Drug Interactions: Sep 2000 (PDF69KB, HTML93KB)
- CTAs for Comparative BA Studies: Draft Oct 2001; updated Feb 2008 (PDF241KB, HTML87KB)
- Records Related to Clinical Trials: May 2006 (PDF137KB, HTML75KB)
- Preparation of Comparative BA Information for Drug Submissions in the CTD Format: Draft May 2004 (PDF91KB, HTML106KB)
Japan (NIHS)
- Clinical Pharmacokinetic Studies of Pharmaceuticals: Jun 2001 (PDF502KB)
- BE Studies for Generic Products: Feb 2012 (PDF177KB, PDF482KB ja, Q&A Document PDF309KB, PDF590KB ja; Nov 2006:
Guideline PDF175KB, PDF480KB ja, Q&A Document PDF407KB ja; Dec 1997: Guideline PDF60KB, HTML109KB)
- Generic Products for Different Strengths of Oral Solid Dosage Forms: Feb 2012 (PDF120KB, PDF377KB ja, Q&A Document PDF161KB, PDF421KB ja; Nov 2006:
Guideline PDF78KB, PDF235KB ja; Q&A Document PDF471KB ja: Feb 2000: Guideline PDF33KB, HTML19KB)
- Formulation Changes of Oral Solid Dosage Forms: Feb 2012 (PDF121KB, PDF374KB ja, Q&A Document PDF161KB, PDF471KB ja; Nov 2006:
Guideline PDF107KB, PDF251KB ja, Q&A Document PDF471KB ja; Feb 2000: Guideline PDF34KB)
- Different Oral Solid Dosage Forms: Feb 2012 (PDF18KB, PDF131KB ja, Q&A Document PDF42KB, PDF145KB ja)
- Generic Products for Ethical Combination Drug Products: Feb 2012 (Q&A Document PDF16KB, PDF101KB ja)
- Different Strengths of Ethical Combination Drug Products and Formulation Changes of Ethical Combination Drug Products: Feb 2012 (Q&A Document PDF56KB, PDF158KB ja)
- Generic Products for Topical Use: Nov 2006 (PDF ja, Q&A Document PDF ja; Nov 2003:
Guideline PDF68KB)
- Adding Dosage Form for Topical Use: Nov 2006 (PDF236KB ja, Q&A Document PDF43KB ja)
- Oral Prolonged Release Dosage Forms: Mar 1988 (PDF53KB)
South Africa (MCC)
- Substitution of Medicines: Apr 2010 (DOC50KB)
- Pharmaceutical and Analytical Guideline*: Jul 2007 (ZIP/DOC76KB)
- Biostudies: Jun 2011 (DOC233KB)
- Dissolution: Mar 2011 (DOC123KB)
Australia (TGA)
- BA and BE: Jun 2011 (PDF237KB)
- Summary of a BA or BE Study: Dec 2002 (PDF107KB)
- Australian Regulatory Guidelines for Prescription Medicines, Appendix 15: Biopharmaceutic Studies: Jun 2004 (PDF178KB)
- Clinical Guidelines of the European Union adopted in Australia: current (HTML)
New Zealand (Medsafe)
- Guidance notes for applicants for consent to distribute new and changed medicines and related products (including BA/BE): Final, Oct 2001 (DOC5.0MB)
- Biostudy Reference Products: Jul 2006 (HTML5KB)
India (CDSCO)
- Bioavailability / Bioequivalence: Current Draft Mar 2005 (PDF106KB),
Draft Mar 2003 (HTML0.99MB)
- Requirements and Guidelines for Permission to Import and / or Manufacture of New Drugs for Sale or to Undertake Clinical Trials: Schedule Y – Amended Version, Jun 2005 (PDF8.7MB, HTML681KB)
- Documents to be submitted for grant of permission to conduct Bioequivalence studies for export purpose: Aug 2009 (DOC92KB)
- GCP: 2005 (HTML834KB)
- Submission of Clinical Trial Application for Evaluating Safety and Efficacy: v1.1 Dec 2008 (PDF704KB)
- CRO registration: Draft Jan 2011 (PDF565KB)
- Inspection of Clinical Trial: Draft Jul 2012 (PDF658KB)
- Amended Checklist for Test Licence Applications effective from 15 June 2011 (PDF69KB)
- Clarification & Amendments in guidance for industry with respect to Post Approval Changes in Biologicals Products: Aug 2010 (PDF147KB)
- Registration of Ethics Committee: Draft Jul 2012 (PDF1.56MB)
- Ethical Guidelines for Biomedical Research on Human Participants (published by the Indian Council of Medical Research): Oct 2006 (PDF3.1MB)
Bangladesh (DGDA)
- Guidance for Industry (Submission of Clinical Trial Application for Evaluating Safety and Efficacy, Requirements for permission of New Drugs Approval, Post approval changes in biological products: Quality safety and Efficacy Documents, Preparation of the Quality Information for Drug Submission for New Drug Approval: Biotechnological/Biological Products): 2010 (PDF555KB)
PAHO
- Good Clinical Practices - Document of the Americas: 2005 (PDF306KB)
- Science Based Criteria for BE in vivo and in vitro, Bio-Waivers and Strategic Framework for Implementation: Draft >2001? (PDF971KB)
- BA / BE / Biowaivers: Final Draft Aug 2004 (PDF868KB)
Brazil (ANVISA)
- Implementation of Relative BA and BE Studies: Apr 2006 (
PDF94KB pt)
- Pharmaceutical Equivalence / Dissolution: Aug 2010 (
PDF101KB pt)
- BA / BE: May 2003 (HTML46KB en, HTML31KB pt)
- Exemption and Substitution of BE Studies (Biowaiver): Aug 2011 (
PDF87KB pt, HTML18KB pt)
- List of candidate drugs for BCS based biowaivers: Aug 2011 (HTML9KB pt)
- Bioanalytical Method Validation: May 2012 (PDF215KB pt)
- Explanation of the Implementation of Re No. 899/2003 – Validation of Bioanalytical Methods: Jun 2008 (PDF34KB pt)
- National Registry of Volunteers in BE Studies: Jun 2008 (HTML26KB pt)
- Statistics for BA/BE Studies: May 2003 (HTML49KB pt)
- Protocol of BE Studies: May 2003 (HTML32KB en, HTML16KB pt,
Mar 2002 HTML28KB pt)
- Report of BE Studies: May 2003 (HTML63KB en, HTML55KB pt)
- List of Reference Products: Current (PDF265KB pt)
- Rules / Technical Regulations for CROs: May 2003 (HTML720KB en, HTML586KB pt)
- Annex I: Certification for BA/BE Centers: (Application Form DOC395KB,
DOC148KB; Renewal Form DOC370KB, RTF365KB)
- Annex II: Guidelines for Inspection at Centers of BA/BE of Medicines (
DOC pt)
- Annex III: Certificate of Good Practices of BA/BE of Medicines (GIF1KB pt)
- Annex IV: Form for Outsourcing of Phase for Assays of BA/BE of Medicines (
DOC pt)
- Annex V: Form for Monthly Report of Assays of BA/BE of Medicines (
DOC pt)
- Guidance for Pharmaceutical Equivalence and Bioequivalence of Nasal Sprays and Aerosols: Oct 2009 (HTML15KB pt)
- Volume 1 (clinics, analytics, statistics): 2002 (ZIP/PDF6.1MB en, ZIP/PDF4.3MB pt)
- Volume 2 (micropipets, water for analysis, instrumentation): 2002 (ZIP/PDF6.2MB en, ZIP/PDF4.7MB pt)
Mexico
Argentina
- GCP Guideline for studies in human subjects: Nov 2007 (PDF201KB es)
GCP in Clinical Studies: 1997, amended 2005 (PDF143KB es)
- Good Practices in Clinical Pharmacology Research: Nov 2010 (PDF1.0MB es)
- BA / BE: Final Sep 2006, amended Mar 2007 (PDF1.8MB es,
1999 PDF389KB es)
- BCS based Biowaivers for oral solid IR dosage forms: Feb 2009 (PDF97KB es)
- Post approval changes: Feb 2009 (PDF154KB es)
- Bioanalytical Method Validation: Sep 2005 (PDF130KB es)
Saudia Arabia
- BE: May 2011 (PDF280KB)
Draft May 2005 (PDF297KB)
- Biowaiver: Draft Sep 2012 (PDF748KB)
- Variation Requirements: Aug 2011 (PDF359KB)
- Guideline on Pharmaceutical Equivalence Requirements: Sep 2010 (PDF107KB)
Draft Aug 2009 (PDF139KB)
- Clinical Trials Requirements Guideline: Draft Oct 2009 (PDF374KB),
Draft May 2005 (PDF318KB)
- Guidelines for IND requirements: Sep 2010 (PDF315KB)
Draft Aug 2009 (PDF318KB)
- GLP: Draft Feb 2006? (PDF269KB)
- Drug Master File Requirements for the Registration of Biosimilars: Draft Aug 2008 (PDF105KB)
- Guidelines on Biosimilars: Dec 2010 (PDF1.2MB)
Draft Oct 2009 (PDF971KB)
Jordan
- Law of clinical studies: 2003 (DOC55KB ar),
2001 (DOC59KB en)
Egypt
- BE Studies Guidelines: Jan 2010 (PDF1.0MB)
- BE Requirements: Mar 2009 (DOC111KB ar)
- BE Report: Oct 2008 (DOC132KB)
- GLP Checklist: Draft Mar 2006 (DOC754KB)
ASEAN States (ACCSQ)
- BA / BE: Final Draft Jul 2004 (PDF243KB)
- BE Studies Reporting Format: Feb 2008 (PDF37KB)
- BE, Q&A: Version 5, Jul 2012 (PDF65KB); Version 4, Jun 2011 (PDF69KB); Version 3, Jul 2010 (PDF11KB); Version 2, May 2009 (PDF67KB); Version 1, Jul 2008 (PDF16KB)
Malaysia (BPFK)
- Conduct of BA and BE Studies: Final, Sep 2000 (PDF89KB, DOC191KB)
- GCP: Second Edition, Jan 2004 (PDF646KB)
- GLP: Jun 2009 (OECD’s adopted; see PDF368KB)
- Guidance Document and Guidelines for Registration of Biosimilars: Aug 2008 (PDF166KB)
Thailand (FDA)
- Guidance for Preparation of the In vivo Bioequivalence Study Report: 2010 (PDF1.4MB)
- BA / BE: Mar 2009 (PDF224KB en/th)
- BA / BE: Current? (HTML146KB th)
BA / BE: Aug 2004(?), adopted 2005 (DOC171KB)
- Instruction for the In Vivo BE Study Protocol Development: Oct 2006 (PDF1.4MB th)
- BE Study Protocol / Report: 2003 (PDF52KB th)
Singapore (HSA, 卫生科学局)
- Drug Registration Information and Guidelines
- Announcement - Revision to Guidance on Medicinal Product Registration in Singapore: Mar 2012 (PDF99KB)
- Guidance on Medicinal Product Registration in Singapore: Apr 2011 (complete document: PDF6.0MB, main document: PDF2.6MB)
- Product Interchangeability and Biowaiver Request for chemical Generic Drug Applications: Feb 2007 (Appendix 15 PDF47KB)
- Guidance on Registration of Similar Biological Products: Aug 2009 (PDF126KB)
- ASEAN Common Technical Requirements (ACTR)
- BA / BE: Final Draft Jul 2004 (PDF127KB)
- Validation of Analytical Procedures: Draft Jan 2007 (PDF123KB)
- ASEAN Guideline on Analytical Validation – Q&A: Version 1, Jun 2012 (PDF145KB)
(South) Korea
- Guidance Document for BE Study: Dec 2008 (PDF604KB)
Minimum Requirements for BE Test: Dec 2005 (PDF493KB)
Taiwan
- Regulations 台灣藥物法規資訊網 zh
- Guidelines for Bioavailability & Bioequivalence (BA/BE) Studies: Apr 2009 (PDF199KB)
BA/BE: Dec 2006 (PDF171KB zh, HTML47KB zh)
- Guideline on the Examination and Registration of Drugs — Guideline on Biosimilar products: Nov 2008 (PDF492KB)
- GCP: Jan 2005 (PDF365KB, PDF248KB zh, HTML230KB zh)
- Pediatric PK: Jul 2002 (PDF195KB zh, HTML158KB zh)
- Ethnic Factors in the Acceptability of Foreign Clinical Data: May 2002 (PDF323KB zh)
- GLP: Mar 2006 (PDF200KB zh, HTML197KB zh)
- Nonclinical Pharmacology/Toxicology: Jun 2000 (PDF1.0MB zh, HTML1.9MB zh)
- Analytical Method Validation: Jan 2000 (PDF223KB zh, HTML172KB zh)
China
- Drug Administration Law: Dec 2001 (HTML64KB)
- Regulations for Implementation of the Drug Administration Law: Sep 2002 (HTML63KB)
- Good Clinical Practice: Aug 2003 (HTML46KB zh)
- Statistical Guidelines for Clinical Trials of Drugs and Biologics: Mar 2005 (PDF324KB zh)
- Pharmacokinetics: 2005 (PDF300KB zh)
- Bioequivalence: 2005 (PDF328KB zh)
- Hong Kong; GCP for Proprietary Chinese Medicines: Feb 2004 (PDF242KB en, PDF669KB zh)
Switzerland
- Instructions for Generics: Dec 2002 (PDF704KB de/fr)
- Reference Formulations for BE / CTDs for Generics: Apr 2004 (PDF659KB de/fr)
- Biosimilars: Feb 2008 (PDF64KB de)
Federal Office of Public Health – AGIT
Guidelines on computerized systems
- Guidelines for the archiving of Electronic Raw Data in a GLP Environment: May 2003 (PDF124KB)
- Guidelines for the management of electronic SOPs in GLP: Sep 2006 (PDF134KB)
- Guidelines for the acquisition and processing of electronic raw data in a GLP environment: Sep 2006 (PDF166KB)
- Guidelines for the validation of computerised Systems in GLP Environment: Dec 2007 (PDF344KB)
Turkey
- Good Laboratory Practice Principles: Jun 2002 (HTML55KB tr)
- Licensing Regulation for Pharmaceutical Products: 2003 (PDF147KB)
- Submission of BA/BE Dossiers: Jan 2006 (
PDF287KB)
Israel
- Guidelines for Clinical Trials in Human Subjects: Jan 2006 (PDF888KB he, PDF204KB en)
- SOP for Performing BE in Human Subjects: Sep 2002 (DOC132KB he)
- Requirments for Registration of a Generic Product: Sep 2002 (DOC167KB he)
Russian Federation
- Drugs Bioequivalence Evaluation: 2008 (PDF193KB)
- Methodological recommendations for drug manufacturers on in vitro equivalence test for generic drug products according to biowaiver procedure: Draft 2010 (PDF221KB)
Uganda
- Guidelines on the Registration of Pharmaceuticals for Human use: Jul 2006 (PDF154KB)
- Variations: Oct 2009 (PDF1.5MB)
OECD
OECD Environmental Health and Safety Publications, Series on Principles of Good Laboratory Practice and Compliance Monitoring
- OECD Principles of Good Laboratory Practice: Apr 1999 (PDFs en, fr, en/fr, de).
- Revised Guides For Compliance Monitoring Procedures for Good Laboratory Practice: Jun 1995 (PDFs en, fr, en/fr).
- Revised Guidance for the Conduct of Laboratory Inspections and Study Audits: Jun 1995 (PDFs en, fr, en/fr).
- Quality Assurance and GLP: Dec 1999 (PDFs en, fr, de, es).
- Compliance of Laboratory Suppliers with GLP Principles: Sep 2000 (PDFs en, fr, de, es).
- The Application of the GLP Principles to Field Studies: Sep 2000 (PDFs en, fr, de, es) – not applicable for PK/BA/BE/PK, just for completeness.
- The Application of the GLP Principles to Short Term Studies: Dec 1999 (PDFs en, fr, de, es).
- The Role and Responsibility of the Study Director in GLP Studies: Oct 1999 (PDFs en, fr, de).
- Guidance for the Preparation of GLP Inspection Reports: Oct 1999 (PDFs en, fr, en/fr).
- The Application of the Principles of GLP to Computerised Systems: Oct 1995 (PDFs en, fr, de, es: 4th link, also denoted as German).
- The Role and Responsibilities of the Sponsor in the Application of the Principles of GLP: Mar 1998 (PDFs en, fr).
- Requesting and Carrying Out Inspections and Study Audits in Another Country: Sep 2000 (PDFs en, fr).
- The Application of the OECD Principles of GLP to the Organisation and Management of Multi-Site Studies: Jun 2002 (PDFs en, fr, de).
- The Application of the Principles of GLP to in vitro Studies: Nov 2004 (PDFs en, fr).
- Establishment and Control of Archives that Operate in Compliance with the Principles of GLP: Jun 2007 (PDFs en, fr).
PIC/S
- Good Practices for Computerized Systems in Regulated “GXP” Environments: Version 3, Sep 2007 (PDF443KB)
EDQM
- Validation of Analytical Procedures: Jun 2005 (PDF605KB)
- Uncertainty of Measurements
- Part I (compliance testing): Dec 2007 (PDF703KB)
- Part II (other than compliance testing): Dec 2007 (PDF1.0MB)
- Qualification of Equipment (core document): Sep 2008 (PDF1.0MB)
- Annex 1: Qualification of HPLC Equipment: Feb 2007 (PDF1.4MB)
- Annex 2: Qualification of GC Equipment: Oct 2006 (PDF897KB)
Abbreviations |
| ACCSQ | Consultative Committee for Standards and Quality (→ ASEAN) |
| AGIT | Arbeitsgruppe Informationstechnologie (Working Group on Information Technology, Switzerland) |
| ANDA | Abbreviated New Drug Application (→ FDA) |
| ANMAT | Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (National Administration for Medicines, Food and Medical Technology, Argentina) |
| ANVISA | Agência Nacional de Vigilância Sanitária (National Agency for Sanitary Monitoring, Brazil) |
| API | Active Pharmaceutical Ingredient |
| ASEAN | Association of Southeast Asian Nations |
| BA | Bioavailability |
| BCS | Biopharmaceutics Classification System |
| BE | Bioequivalence |
| BPFK | Biro Pengawalan Farmaseutikal Kebangsaan (National Pharmaceutical Control Bureau, Malaysia) |
| CDE | Center For Drug Evaluation (Taiwan) |
| CDER | Center for Drug Evaluation and Research (of the → FDA) |
| CDSCO | Central Drugs Standard Control Organization (India) |
| CHMP | Committee for Medicinal Products for Human Use (of the → EMA) |
| CRO | Contract Research Organization |
| CTA | Clinical Trial Application |
| CTD | Common Technical Document (according to → ICH) |
| DCD | Drug Control Division (Thailand) |
| DCP | Decentralised Procedure (in the → EU) |
| DGDA | Directorate General of Drug Administration (Bangladesh) |
| DOC | Micro$oft’s Word Format |
| DKMA | Danish Medicines Agency |
| E | Efficacy (Topic of → ICH) |
| eCTD | Electronic Common Technical Document (→ CTD) |
| EDA | Egyptian Drug Authority |
| EDQM | European Directorate for the Quality of Medicines & HealthCare |
| EEA | European Economic Area |
| EMA | European Medicines Agency (formerly European Medicines Evaluation Agency – EMEA) |
| ER | Extended Release |
| EU | European Union |
| EWP | Efficacy Working Party (of the → EMA) |
| FDA | Food and Drug Administration (United States) |
| FIM | First-In-Man (Clinical Study) |
| GCP | Good Clinical Practice(s) |
| GLP | Good Laboratory Practice(s) |
| GIF | Graphics Interchange Format |
| GMP | Good Manufacturing Practice(s) |
| HPFB | Health Products and Food Branch (of Health Canada) |
| HSA | Health Sciences Authority (Singapore) |
| HVD | Highly Variable Drug |
| HVDP | Highly Variable Drug Product |
| ICH | International Conference on Harmonisation (of Technical Requirements for the Registration of Pharmaceuticals for Human Use) |
| IMP | Investigational Medicinal Product |
| IND | Investigational New Drug |
| IR | Immediate Release |
| IRB | Institutional Review Board |
| JPEG | Joint Photographic Experts Group (graphics format) |
| JFDA | Jordan Food and Drug Administration |
| KB | Kilobyte = 1,024 Bytes (filesize) |
| KFDA | (South) Korea Food & Drug Administration |
| MA | Marketing Authorisation (in the → EU) |
| MB | Megabyte = 1,024KB = 1,048,576 Bytes (filesize) |
| MCC | Medicines Control Council (South Africa) |
| MoH | Ministry of Health |
| MR | Modified Release |
| MRP | Mutual Recognition Procedure (in the → EU) |
| NDA | National Drug Authority (Uganda) |
| NfG | Note for Guidance (of the → EMA) |
| NIHS | National Institute for Health Sciences (Japan) |
| NIMP | Non Investigational Medicinal Product |
| OECD | Organisation for Economic Co-operation and Development |
| OGD | Office of Generic Drugs (of the → FDA) |
| PAHO | Pan American Health Organization |
| PDF | Adobe’s Portable Document Format |
| PIC/S | Pharmaceutical Inspection Co-operation Scheme |
| PK | Pharmacokinetics |
| Q | Quality (Topic of → ICH) |
| Q&A | Questions and Answers |
| RTF | Rich Text Format |
| SFDA | Saudi Food & Drug Authority (Saudia Arabia) |
| SFDA | State Food & Drug Administration (China) |
| SOPitis | Inflammation of a CRO in order to comply with written instructions rather than following common sense |
| SS | Semisolid |
| SUPAC | Scale-Up and Post-Approval Changes (according to → FDA) |
| TGA | Therapeutic Goods Administration (Australia) |
| TIFF | Tagged Image File Format |
| TPD | Therapeutic Products Directorate (of → HPFB) |
| WHO | World Health Organization |
| ZIP | Compressed file (format) |